

***Pattern Visual Evoked Potential in Diffuse Diabetic
Macular Edema before and after Modified Grid Laser
Treatment by Argon and Subthreshold Micropulse Diode
Laser***

Thesis

Submitted in Partial Fulfilment of M.D Degree
In Ophthalmology

By
Teresa Kamal Asaad
M.B.B.ch., M.Sc.

Supervisors

Prof. Dr Hosam Eldin Zaki Anis
Professor of Ophthalmology
Faculty of Medicine, Cairo University

Prof .Dr Onsi Alfy Badie
Professor of Ophthalmology
Research Institute of Ophthalmology

Prof. Dr Hany Salah Eldin Hamza
Professor of Ophthalmology
Faculty of Medicine, Cairo University

Faculty of Medicine
Cairo University
2008

Acknowledgement

I want to start by thanking God for giving me help.

I would like to mention my gratitude to our late Professor Dr Hosam Anis and to also express my deepest regrets for his sudden loss. I am grateful for his enormous guidance and wise advice during the course of this work .

I want to forward my gratitude to Professor Dr Onsi Alfy Badie . I want to thank him for his continuous support, effort , hard work, zeal and challenge with which he guided the part of the study that was done at the Research Institute of Ophthalmology, and also in the study as a whole .

I am also very grateful to Professor Dr Hany Salah Eldin Hamza for all the precious time he spared for the part of the study done in the Diagnostic Laser Unit–Faculty of Medicine, Cairo University. I want to thank him also for his patience, tolerance and continuous encouragement along the way and his persistence to make this work come out in an organized manner.

It has been a great privilege to attempt the study under the supervision of my professors to whom I owe a lot.

I am thankful to Dr Fatheya Alhalawany who conducted the statistical analysis of the study.

Finally, I am truly grateful to all the people, both friends and colleagues at the Research institute of Ophthalmology and at the Diagnostic Laser Unit - Faculty of Medicine, Cairo University, who were always very kin to help and ease the procedures. Their kind help enabled me to conduct the practical part of the study.

I am thankful to my late father who was always very encouraging and would have so much wanted to see the completion of this work .I am also very thankful to my mother and the rest of my loving family.

*Dedicated
To
Our Late Professor Dr Hosam Eldin Zaki Anis
To whom I owe a lot*

Abstract

The aim of this study was to evaluate the electrophysiological changes in diffuse diabetic macular oedema using pattern visual evoked potential before and after laser treatment using modified grid laser treatment. Cases were followed up over 6 months follow up period by clinical examination, pattern visual evoked potential and flourescein angiogram. The types of laser used for the different groups were the classic argon laser, the mild argon laser or the subthreshold micropulse diode laser treatment. The study highlight the effect of the different types of laser on the electrophysiological function of the macular, and also the effectiveness of these types of laser on the resolution of diabetic macular oedema.

Key Words: Pattern visual evoked potential- diabetic macular oedema- argon laser - subthreshold micropulse diode laser

Content

<i>Topic</i>	<i>Page</i>
• <i>Aim of Work.....</i>	<i>16</i>
• <i>Introduction.....</i>	<i>17</i>
• <i>Anatomy and Physiology.....</i>	<i>18</i>
• <i>Macular Function Tests</i>	<i>30</i>
• <i>Epidemiology, Risk Factors and Pathogenesis of Diabetic Retinopathy.....</i>	<i>47</i>
• <i>Classification of Diabetic Retinopathy.....</i>	<i>82</i>
• <i>Effect of Diabetes on the macular Function.....</i>	<i>91</i>
• <i>Different modalities for the Treatment of Diabetic Macular Edema.....</i>	<i>97</i>
• <i>Fundus Fluorescein Angiogram in Diabetic Macular Edema..</i>	<i>118</i>
• <i>Subjects and Methods.....</i>	<i>123</i>
• <i>Results</i>	<i>132</i>
• <i>Discussion.....</i>	<i>220</i>
• <i>Summary.....</i>	<i>231</i>
• <i>References.....</i>	<i>234</i>

List of Figures

Figures	Page
• 1:1- The different zones of the macula.....	19
• 1:2-Vertical section in the human macula	21
• 1:3-Inner blood retinal barrier	24
• 1:4-Outer blood retinal barrier.....	26
• 1:5-Transepithelial transport of ions across the RPE.....	28
• 2:1- Sinusoidal wave of flicker stimulus.....	36
• 2:2-Photopic single flash cone response.....	37
• 2:3-mERG demonstrating the central 5 degrees of the macula.....	38
• 2:4a- Matrix of mERG.....	39
• 2:4b- 3 dimensional scaler plot of mERG.....	39
• 2:5-Sketch of the basic elements of VEP recording connections.....	41
• 2:6-Transient pattern VEP.....	42
• 2:7-Steady state pattern VEP.....	43
• 2:8- The VEP waveform	44
• 3:1 - Trypsin digest demonstrating the microaneurysms with adjacent acellular tubules.....	61
• 3:2- Extensive IRMA.....	66
• 3:3-Venous changes in diabetic retinopathy.....	67
• 3:4-Macular oedema developing in the juxtacapillary region.....	72
• 3:5-Vascular and neuronal interdependent changes in diabetic retinopathy.....	78
• 4:1-Clinically Significant Macular Edema.....	85
• 4:2- Colored photography focal macular edema with circinate hard exudates	87
• 4:3- Colored photography diffuse macular edema.....	88

- *5:1-Multifocal ERG of diabetic individual and control individual90*
- *6:1- Argon laser focal treatment.....107*
- *6:2-Modified grid laser treatment109*
- *6:3-Combined modified grid laser treatment and PRP- 2 year follow up.....113*
- *7:1-Fundus fluorescein angiogram of focal leakage.....119*
- *7:2- Fundus fluorescein angiogram of diffused leakage, early and late.....120*
- *7:3-Late frames of fundus fluorescein angiogram in cystoid macular edema.....120*
- *7:4- Fundus fluorescein angiogram of PDR with ischemic maculopathy.....122*
- *8:1-Topcon TRX50 retinal camera.....125*
- *8:2-RETI VEP machine.....125*
- *8:3a&b- Preamplifier of the PVEP machine.....126*
- *8:4- PVEP monitor with the checker size of 16x16.....127*
- *8:5-Electrodes used for the PVEP procedure.....127*
- *8:6- Zeiss argon laser machine.....129*
- *9:1-Line graph of BSCVA ,Prelaser,1 month and 6months[GroupA]144*
- *9:2-Line graph of BSCVA ,Prelaser,1 month and 6 months[GroupB].....154*
- *9:3-Line graph of BSCVA ,Prelaser,1 month and 6 months[GroupC].....164*
- *9:4-Line graph means of BSCVA ,Prelaser,1 month 6months[3 Groups].....174*
- *9:5-Line graph means of N75,Prelaser,1 month and 6months[3 Groups].....177*
- *9:6-Line graph means of P100,Prelaser,1 month and 6 months[3 Groups].....180*

- *9:7-Line graph means of N135 ,Prelaser,1 month and
6 months[3 Groups].....182*
- *9:8-Line graph means of N75-P100 ,Prelaser,1 month and
6 months[3 Groups].....185*
- *9:9-Line graph means of P100-N135 ,Prelaser,1 month and
6 months[3 Groups].....187*

List of Charts

<i>Chart</i>	<i>Page</i>
• 9:1-Bar chart of means of N75 prelasers, 1 month and 6 months [Group A].....	145
• 9:2-Bar chart of means of P100 prelasers, 1 month and 6 months [Group A].....	147
• 9:3-Bar chart of means of N135 prelasers, 1 month and 6 months [Group A].....	148
• 9:4-Bar chart of means of N75-P100 prelasers, 1 month and 6 months [Group A].....	150
• 9:5-Bar chart of means of P100-N135 prelasers, 1 month and 6 months [Group A].....	151
• 9:6-Pie chart of macular at 1 month [Group A].....	153
• 9:7-Pie chart of macular at 6 months [Group A].....	153
• 9:8-Bar chart of means of N75 prelasers, 1 month and 6 months [Group B].....	156
• 9:9-Bar chart of means of P100 prelasers, 1 month and 6 months [Group B].....	157
• 9:10-Bar chart of means of N135 prelasers, 1 month and 6 months [Group B].....	158
• 9:11-Bar chart of means of N75-P100 prelasers, 1 month and 6 months [Group B].....	160
• 9:12-Bar chart of means of P100-N135 prelasers, 1 month and 6 months [Group B].....	162
• 9:13-Pie chart of macular at 1 month [Group B].....	163
• 9:14-Pie chart of macular at 6 months [Group B].....	163
• 9:15-Bar chart of means of N75 prelasers, 1 month and 6 months [Group C].....	166

- **9:16-Bar chart of means of P100 prelaser,1month and 6months[GroupC].....167**
- **9:17-Bar chart of means of N135 prelaser,1month and 6months[GroupC].....169**
- **9:18-Bar chart of means of N75-P100 prelaser,1month and 6months[GroupC].....170**
- **9:19-Bar chart of means of P100-N135 prelaser,1month and 6months[GroupC].....172**
- **9:20-Pie chart of macular at 1month[GroupC].....173**
- **9:21-Pie chart of macular at 6months[GroupC].....173**
- **9:22-Bar chart of macular at 1month[3 Groups].....190**
- **9:23-Bar chart of macular at 6months[3 Groups].....191**

List of Tables

<i>Table</i>	<i>Page</i>
• 9:1-Sex difference in percentage for the groups.....	133
• 9:2-Age range for the groups.....	134
• 9:3-Type of diabetes in percentage	134
• 9:4-Duration of diabetes	135
• 9:5-Prelaser BSCVA.....	136
• 9:6-P value for the comparative analysis of BSCVA between diabetic group and the control group.....	136
• 9:7-PVEP for group A before laser treatment.....	137
• 9:8-PVEP for group B before laser treatment.....	137
• 9:9-PVEP for group C before laser treatment.....	138
• 9:10-PVEP for the control group	138
• 9:11-P value for the comparative analysis of N75 between diabetic group and the control group	139
• 9:12-P value for the comparative analysis of P100 between diabetic group and the control group	140
• 9:13-P value for the comparative analysis of N135 between diabetic group and the control group	140
• 9:14-P value for the comparative analysis of N75-P100 between diabetic group and the control group	141
• 9:15-P value for the comparative analysis of P100-N135 between diabetic group and the control group	142
• 9:16-Mean shots /eye for each group.....	143
• 9:17-Means of BSCVA Prelaser, 1 month and 6 months [GroupA].....	143
• 9:18-P value for comparative analysis of BSCVA before and after laser treatment[GroupA].....	144
• 9:19-Means of N75 Prelaser, 1 month and 6 months [GroupA].....	145
• 9:20-P value for comparative analysis of N75 before and after laser treatment[GroupA].....	146
• 9:21-Means of P100 Prelaser, 1 month and 6 months [GroupA].....	146

- 9:22-P value for comparative analysis of P100 before and after laser treatment[GroupA].....147
- 9:23-Means of N135,Prelaser, 1 month and 6 months [GroupA].....148
- 9:24-P value for comparative analysis of N135 before and after laser treatment[GroupA].....149
- 9:25-Means of N75-P100 Prelaser, 1 month and 6 months [GroupA].....149
- 9:26-P value for comparative analysis of N75-P100 before and after laser treatment[GroupA].....150
- 9:27-Means of P100-N135 Prelaser, 1 month and 6 months [GroupA].....151
- 9:28-P value for comparative analysis of P100-N135 before and after laser treatment[GroupA].....152
- 9:29-Resolving/persistent macular oedema after laser treatment[GroupA].....152
- 9:30-Means of BSCVA Prelaser, 1 month and 6 months [GroupB].....154
- 9:31-P value for comparative analysis of BSCVA before and after laser treatment[GroupB].....155
- 9:32-Means of N75 Prelaser, 1 month and 6 months [GroupB].....155
- 9:33-P value for comparative analysis of N75 before and after laser treatment[GroupB].....156
- 9:34-Means of P100 Prelaser, 1 month and 6 months [GroupA].....157
- 9:35-P value for comparative analysis of P100 before and after laser treatment[GroupB].....158
- 9:36-Means of N135,Prelaser, 1 month and 6 months [GroupB].....158
- 9:37-P value for comparative analysis of N135 before and after laser treatment[GroupB].....159
- 9:38-Means of N75-P100 Prelaser, 1 month and 6 months [GroupB].....160
- 9:39-P value for comparative analysis of N75-P100 before and after laser treatment[GroupB].....161
- 9:40-Means of P100-N135 Prelaser, 1 month and 6 months [GroupB].....161
- 9:41-P value for comparative analysis of P100-N135 before and after laser treatment[GroupB].....162
- 9:42-Resolving/persistent macular oedema after laser treatment[GroupB]...163

- 9:43-Means of BSCVA Prelaser, 1 month and 6 months [GroupC].....164
- 9:44-P value for comparative analysis of BSCVA before and after laser treatment[GroupC].....165
- 9:45-Means of N75 Prelaser, 1 month and 6 months [GroupC].....165
- 9:46-P value for comparative analysis of N75 before and after laser treatment[GroupC].....166
- 9:47-Means of P100 Prelaser, 1 month and 6 months [GroupC].....167
- 9:48-P value for comparative analysis of P100 before and after laser treatment[GroupC].....168
- 9:49-Means of N135,Prelaser, 1 month and 6 months [GroupC].....168
- 9:50-P value for comparative analysis of N135 before and after laser treatment[GroupC].....169
- 9:51-Means of N75-P100 Prelaser, 1 month and 6 months [GroupC].....170
- 9:52-P value for comparative analysis of N75-P100 before and after laser treatment[GroupC].....171
- 9:53-Means of P100-N135 Prelaser, 1 month and 6 months [GroupC].....171
- 9:54-P value for comparative analysis of P100-N135 before and after laser treatment[GroupC].....172
- 9:55-Resolving/persistent macular oedema after laser treatment[GroupC].....173
- 9:56- BSCVA before and after laser treatment [GroupA,B & C].....174
- 9:57-P value for comparative analysis of BSCVA before and after laser treatment[Group A,B & C].....175
- 9:58-P value for comparative analysis of BSCVA at 1 month & 6 months[Group A,B & C].....175
- 9:59- N75 before and after laser treatment [GroupA,B & C].....176
- 9:60-P value for comparative analysis of N75before and after laser treatment[Group A,B & C].....177
- 9:61-P value for comparative analysis of N75 at 1 month & 6 months [GroupA,B&C].....178
- 9:62- P100 before and after laser treatment [GroupA,B & C].....179
- 9:63-P value for comparative analysis of P100 before and after laser treatment [Group A,B & C].....180

- 9:64- *P* value for comparative analysis of P100 at 1 month & 6 months[GroupA,B&C].....181
- 9:65- N135 before and after laser treatment [GroupA,B & C].....182
- 9:66- *P* value for comparative analysis of N135 before and after laser treatment [Group A,B & C].....183
- 9:67- *P* value for comparative analysis of N135 at 1 month & 6 months[GroupA,B&C].....183
- 9:68- N75-P100 before and after laser treatment [GroupA,B & C].....184
- 9:69- *P* value for comparative analysis of N75-P100 before and after laser treatment [Group A,B & C].....185
- 9:70- *P* value for comparative analysis of N75- P100 at 1 month & 6 months[GroupA,B&C].....186
- 9:71- P100-135 before and after laser treatment [GroupA,B & C].....187
- 9:72- *P* value for comparative analysis of P100-135 before and after laser treatment [Group A,B & C].....188
- 9:73- *P* value for comparative analysis of P100-135 at 1 month & 6 months[GroupA,B&C].....188
- 9:74- Resolving/persistent macular oedema at 1 month for the different groups189
- 9:75- Resolving/persistent macular oedema at 6 months for the different groups.....190
- 9:76- *P* value for comparative analysis of Resolving/persistent macular oedema for the different groups.....191
- 9.77- Number of laser sessions for each eye.....193

Abbreviations

- ***AGE-Advanced glycated end products***
- ***BRB-Blood retinal barrier***
- ***BSCVA-Best spectacle corrected visual acuity***
- ***BUN-Blood urea nitrogen***
- ***CME-Cystoid macular edema***
- ***CRA-Central retinal artery***
- ***CSME-Clinically Significant Macular Edema***
- ***DCCT-Diabetic Control and Complication Trial***
- ***DDME-Diffused diabetic macular oedema***
- ***ET-1-Endothelin-1***
- ***ETDRS-Early Treatment Diabetic Retinopathy Study Group***
- ***FAO-Flucocinolone acetonide envision***
- ***FAZ-Foveal avascular zone***
- ***HIF-Hypoxia inducible factors***
- ***HLA-Human leucocytic antigen***
- ***HRC-High risk criteria***
- ***ICAM- Intracellular adhesion molecules***
- ***IDDM-Insulin dependent diabetes mellitus***
- ***IGF-Insulin like growth factor***
- ***ILM-Internal limiting membrane***
- ***INL-Inner nuclear layer***
- ***IPL-Inner plexiform layer***
- ***IRMA-Intraretinal microvascular abnormalities***
- ***MAR-Minimal angle of resolution***
- ***mERG- Multifocal electroretinogram.***
- ***MVL-Moderate visual loss***
- ***NIDDM-Non-insulin dependent diabetes mellitus***
- ***NVD-Neovessels at disc***